Pharmacogenetics in modern psychiatry.
There is no unique scientific agreement about genetic variations that could beyond any doubt predict phenotype of the response to pharmacotherapy. The knowledge about the predictors for therapy and serious adverse effects could be very useful in clinical practice. It is obvious that the combination of variation in metabolizing enzymes, transporter proteins and drug targets fully explains heterogeneity in response to psychiatric treatment. We assume that genetic polymorphisms of serotoninergic transporter and MDR1 could be important in prediction of therapeutic response in patients with major depression treated with paroxetine. Our results show that SERTPR-LL genotype might predispose significantly better paroxetine treatment response compared to SS genotype in MDD patients and that variants G2677T and C3435T are not associated with therapeutic response to paroxetine in patients with major depressive disorder.